Abstract:Coronavirus disease 2019 or COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a significant threat to the health of human beings. While wearing mask, maintaining social distance and performing self-quarantine can reduce virus spreading passively, vaccination actively enhances immune defense against COVID-19. However, mutations of SARS-CoV-2 and presence of asymptomatic carriers frustrate the effort of completely conquering COVID-19. A strategy that can reduce the susceptibility and thus prevent COVID-19 while blocking viral invasion and pathogenesis independent of viral antigen stability is highly desirable. In the pathogenesis of COVID-19, endocrine disorders have been implicated. Correspondingly, many hormones have been identified to possess therapeutic potential of treating COVID-19, such as estrogen, melatonin, corticosteroids, thyroid hormone and oxytocin. Among them, oxytocin has the potential of both treatment and prevention of COVID-19. This is based on oxytocin promotion of immune-metabolic homeostasis, suppression of inflammation and pre-existing comorbidities, acceleration of damage repair, and reduction of individuals' susceptibility to pathogen infection. Oxytocin may specifically inactivate SARS-COV-2 spike protein and block viral entry into cells via angiotensin-converting enzyme 2 by suppressing serine protease and increasing interferon levels and number of T-lymphocytes. In addition, oxytocin can promote parasympathetic outflow and the secretion of body fluids that could dilute and even inactivate SARS-CoV-2 on the surface of cornea, oral cavity and gastrointestinal tract. What we need to do now is clinical trials. Such trials should fully balance the advantages and disadvantages of oxytocin application, consider the time- and dose-dependency of oxytocin effects, optimize the dosage form and administration approach, combine oxytocin with inhibitors of SARS-CoV-2 replication, apply specific passive immunization, and timely utilize efficient vaccines. Meanwhile, blocking COVID-19 transmission chain and developing other efficient anti-SARS-CoV-2 drugs are also important. In addition, relative to the complex issues with drug applications over a long term, oxytocin can be mobilized through many physiological stimuli, and thus used as a general prevention measure. In this review, we explore the potential of oxytocin for treatment and prevention of COVID-19 and perhaps other similar pathogens.

Intertwined Associations Between Oxytocin, Immune System and Major Depressive Disorder

The association of oxytocin with major depressive disorder: role of confounding effects of antidepressants

Direct Involvement of Androgen Receptor in Oxytocin Gene Expression: Possible Relevance for Mood Disorders.

Different Oxytocin and Corticotropin-Releasing Hormone System Changes in Bipolar Disorder and Major Depressive Disorder Patients

Immunotherapy for depression: Recent insights and future targets

Identifying Key Biomarkers and Therapeutic Candidates for Post-Covid-19 Depression Through Integrated Omics and Bioinformatics Approaches

Neuroimmune Advance in Depressive Disorder

Oxytocin: An Old Hormone, A Novel Psychotropic Drug And Possible Use In Treating Psychiatric Disorders.

[Update on Immune and Metabolic Dysregulation in Major Depressive Disorder and the Implications for Drug Intervention].

Potential of Endogenous Oxytocin in Endocrine Treatment and Prevention of COVID-19

Oxytocin System in Neuropsychiatric Disorders: Old Concept, New Insights.

Gut-brain axis in depression: Crosstalk between neuroinflammation and gut microbiota

Affective Immunology: The Crosstalk Between Microglia and Astrocytes Plays Key Role?

Identification of the Shared Molecular Mechanisms Between Major Depressive Disorder and COVID-19 from Postmortem Brain Transcriptome Analysis.

Research Progress on Mechanisms of Modulating Gut Microbiota to Improve Symptoms of Major Depressive Disorder

Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection

Integrated multi-omics analysis reveals gut microbiota dysbiosis and systemic disturbance in major depressive disorder

A pilot exploration of multi-omics research of gut microbiome in major depressive disorders

Is there a common pathophysiological mechanism between COVID-19 and depression?

Neuroendocrine-immune Connection between Depression and Metabolic Syndrome

The Role of Oxytocin in Early-Life-Stress-Related Neuropsychiatric Disorders